See every side of every news story

Published 10 days ago • loading... • Updated 10 days ago

Harbour BioMed Announces Business Progress and Update

Harbour BioMed expects total profit for the year ended December 31, 2024, to be between RMB7.3 million and RMB22 million, based on preliminary reviews.
The company achieved a record-high cash profit of RMB220 million, indicating strong financial health and operational efficiency.
In 2025, Harbour BioMed repurchased 8,146,000 shares for nearly HK$30 million, reflecting confidence in its business outlook.
Dr. Jingsong Wang, Founder, Chairman and CEO, stated that the company is transforming into a sustainably profitable global biotech engine.

Insights by Ground AI

Does this summary seem wrong?

18 Articles

18 Articles

All

Left

2

Center

6

Right

2

Charleston Gazette-Mail

+17 Reposted by 17 other sources

Harbour BioMed Announces Business Progress and Update

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the…

10 days ago·Charleston, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources18

Leaning Left2Leaning Right2Center6Last Updated9 days agoBias Distribution

60% Center

Bias Distribution

60% of the sources are Center

60% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Charleston Gazette-Mail broke the news in Charleston, United States 10 days ago on Friday, February 14, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics